CD274 and non-small cell lung carcinoma: Finally, the phase III OAK study showed that atezolizumab in previously treated patients with NSCLC improved OS compared to docetaxel (13.8 vs 9.6 months; HR 0.73, 95% CI 0.62–0.87, p = 0.0003), and furthermore, this benefit was independent of histology and PD-L1 [65,66].